𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

✍ Scribed by Chung, C. H.; Lee, J. W.; Slebos, R. J.; Howard, J. D.; Perez, J.; Kang, H.; Fertig, E. J.; Considine, M.; Gilbert, J.; Murphy, B. A.; Nallur, S.; Paranjape, T.; Jordan, R. C.; Garcia, J.; Burtness, B.; Forastiere, A. A.; Weidhaas, J. B.

Book ID
125840216
Publisher
Oxford University Press
Year
2014
Tongue
English
Weight
199 KB
Volume
25
Category
Article
ISSN
0923-7534

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II trial of cisplatin and vinore
A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
✍ Enrique Espinosa; Pilar Zamora; Alfredo MillΓ‘; Serafin Morales; Raquel Molina; M πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 75 KB πŸ‘ 2 views

## Abstract ## Objective. We assessed the response rate and the toxicity of cisplatin plus vinorelbine in patients with this condition. ## Patients and Method. Forty‐two patients were included. Therapy consisted of cisplatin, 100 mg/m^2^ on day 1, and vinorelbine, 25 mg/m^2^ on days 1 and 8, giv